What is the recommended treatment regimen for Helicobacter pylori infection in an adult patient without drug allergies?

H. pylori Treatment Recommendation

For treatment-naive adult patients without drug allergies, bismuth quadruple therapy (BQT) for 14 days is the preferred first-line regimen when antibiotic susceptibility is unknown. 1

First-Line Treatment Options

The 2024 ACG guidelines establish BQT as the gold standard empiric therapy, consisting of:

• PPI (standard dose twice daily)
• Bismuth subsalicylate (~300mg four times daily)
• Metronidazole 500mg three to four times daily (1.5-2g total daily)
• Tetracycline 500mg four times daily
• Duration: 14 days 1, 2

Alternative First-Line Regimens

If BQT is unavailable or unsuitable, two alternatives exist:

1. Rifabutin triple therapy (14 days):

   • PPI (standard dose twice daily)
   • Amoxicillin 1000mg twice daily
   • Rifabutin 150mg twice daily or 300mg once daily
   • This is particularly valuable because rifabutin and amoxicillin resistance remain rare 3, 1

2. Potassium-competitive acid blocker (PCAB) dual therapy (14 days):

   • Vonoprazan-based regimens (where available)
   • Amoxicillin at high doses
   • This represents a newer option with promising efficacy 1

Regimens to AVOID as First-Line

Clarithromycin-based triple therapy should be avoided due to clarithromycin resistance now exceeding 30% in North America 4. This includes:

• Traditional PPI + amoxicillin + clarithromycin
• Concomitant therapy (unless local resistance data shows <15% clarithromycin resistance)

Similarly, levofloxacin-based regimens are not recommended first-line given resistance rates also exceeding 30% 4.

Critical Implementation Details

Dosing Optimization

• PPI timing: Administer 30 minutes before meals on an empty stomach 3
• Amoxicillin dosing: Use at least 2g daily divided three to four times daily to avoid low trough levels 3
• Metronidazole dosing: When used, ensure adequate dosing of 1.5-2g daily in divided doses, particularly with bismuth therapy, as this improves success despite in vitro resistance 3
• High-dose PPIs: Consider double standard doses or PPIs not metabolized by CYP2C19 for better acid suppression 3

Duration Matters

14-day regimens consistently outperform shorter durations (e.g., 7 or 10 days) across all treatment types 2. The Toronto Consensus specifically recommends 14 days for all first-line treatments to maximize first-attempt success 2.

Treatment Failure Management

After First Treatment Failure

If BQT was used first-line and failed:

• Levofloxacin triple therapy (14 days) OR
• Rifabutin triple therapy (14 days) OR
• Alternative bismuth quadruple regimen with different antibiotics 3

Critical caveat: Avoid levofloxacin if the patient has ANY prior fluoroquinolone exposure for any indication, as resistance likelihood is high 3.

After Second Treatment Failure

Antibiotic susceptibility testing should be performed after two failed therapies with confirmed adherence 3, 1. This guides selection of subsequent regimens and prevents further empiric failures.

Options after susceptibility testing include:

• Rifabutin-based regimens (resistance remains rare)
• High-dose dual therapy: Amoxicillin 2-3g daily in 3-4 divided doses + high-dose PPI twice daily for 14 days 3
• Susceptibility-guided clarithromycin or levofloxacin regimens (only if confirmed susceptible) 1

Common Pitfalls to Avoid

1. Inadequate adherence assessment: Complex regimens with multiple pills confuse patients. Explicitly explain dosing, expected side effects, and importance of completion before prescribing 3

2. Insufficient acid suppression: This is a major cause of treatment failure. Use high-dose PPIs or more potent formulations in refractory cases 3

3. Ignoring antibiotic history: Any prior macrolide exposure (even for respiratory infections) makes clarithromycin-based regimens futile. Any prior fluoroquinolone exposure similarly compromises levofloxacin regimens 3

4. Penicillin allergy labels: In the absence of anaphylaxis history, consider penicillin allergy testing to potentially enable amoxicillin use, as it's crucial for multiple effective regimens 3

5. Skipping test-of-cure: Always confirm eradication with testing 4+ weeks after treatment completion 1

Special Considerations

For vulnerable populations (elderly, multiple comorbidities), shared decision-making becomes important after multiple treatment failures, weighing eradication benefits against repeated antibiotic exposure risks 3. However, for initial treatment in otherwise healthy adults, proceed directly with optimized BQT for 14 days without hesitation.